Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (591-600 of 600) with videos related to

Pageof 60
Sort By:
You have reached the last page of results.This site can display upto 600 results.
Annals of the Rheumatic Diseases|August 12, 2010
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeDaniel Aletaha, Tuhina Neogi, Alan J Silman, et al.
Arthritis and Rheumatism|September 28, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological reportTuhina Neogi, Daniel Aletaha, Alan J Silman, et al.
Annals of the Rheumatic Diseases|February 5, 2011
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
Arthritis and Rheumatism|February 5, 2011
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
Annals of the Rheumatic Diseases|August 11, 2022
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an updateDaniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases|May 14, 2015
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceJosef S Smolen, Ferdinand C Breedveld, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases|March 8, 2017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateJosef S Smolen, Robert Landewé, Johannes Bijlsma, et al.
Annals of the Rheumatic Diseases|January 24, 2020
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateJosef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, et al.
JCI Insight|January 23, 2026
Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of deathOlivia Lenoir, Florence Morin, Anouk Walter-Petrich, et al.
Eclinicalmedicine|March 30, 2022
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study groupOlivier Hermine, Xavier Mariette, Raphael Porcher, et al.
Pageof 60

Showing results (591-600 of 600) with videos related to

Sort By:
Pageof 60
You have reached the last page of results.This site can display upto 600 results.
Annals of the Rheumatic Diseases|August 12, 2010
2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeDaniel Aletaha, Tuhina Neogi, Alan J Silman, et al.
Arthritis and Rheumatism|September 28, 2010
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological reportTuhina Neogi, Daniel Aletaha, Alan J Silman, et al.
Annals of the Rheumatic Diseases|February 5, 2011
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
Arthritis and Rheumatism|February 5, 2011
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trialsDavid T Felson, Josef S Smolen, George Wells, et al.
Annals of the Rheumatic Diseases|August 11, 2022
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an updateDaniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases|May 14, 2015
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceJosef S Smolen, Ferdinand C Breedveld, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases|March 8, 2017
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 updateJosef S Smolen, Robert Landewé, Johannes Bijlsma, et al.
Annals of the Rheumatic Diseases|January 24, 2020
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 updateJosef S Smolen, Robert B M Landewé, Johannes W J Bijlsma, et al.
JCI Insight|January 23, 2026
Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of deathOlivia Lenoir, Florence Morin, Anouk Walter-Petrich, et al.
Eclinicalmedicine|March 30, 2022
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study groupOlivier Hermine, Xavier Mariette, Raphael Porcher, et al.
Pageof 60